Pacific Biosciences of California, Inc. (PACB)
PACB Stock Price Chart
Explore Pacific Biosciences of California, Inc. interactive price chart. Choose custom timeframes to analyze PACB price movements and trends.
PACB Company Profile
Discover essential business fundamentals and corporate details for Pacific Biosciences of California, Inc. (PACB) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Medical - Devices
IPO Date
27 Oct 2010
Employees
575.00
Website
https://www.pacb.comCEO
Christian O. Henry
Description
Pacific Biosciences of California, Inc. (PACB) specializes in pioneering and manufacturing advanced genetic sequencing platforms, empowering researchers and institutions to unravel intricate genetic challenges. At the heart of its offerings are the proprietary PacBio Sequencing Systems, designed for executing, monitoring, and interpreting biochemical sequencing reactions. Complementing these instruments are essential consumable products, such as their unique single molecule real-time (SMRT) cells. Furthermore, the company supplies a comprehensive suite of workflow-specific reagent kits. These include template preparation kits, which utilize molecular biology reagents (like ligase, buffers, and exonucleases) to convert DNA into SMRTbell double-stranded DNA libraries. Binding kits, featuring modified DNA polymerase, facilitate the crucial attachment of SMRTbell libraries to the polymerase in readiness for sequencing. Finally, specialized sequencing kits contain all necessary reagents, including phospholinked nucleotides, for real-time sequencing directly on their instruments. Pacific Biosciences caters to a broad global clientele, encompassing prominent research institutions, commercial diagnostic laboratories, large-scale genome centers, public health organizations, hospitals, clinical research institutes, contract research organizations (CROs), academic bodies, pharmaceutical firms, and agricultural enterprises. Product commercialization is managed through a direct sales force across North America and Europe, complemented by a robust network of distribution partners spanning Asia, the Middle East, Africa, and Latin America. A significant strategic alliance includes a development and commercialization agreement with Invitae Corporation. Originally incorporated in 2000 as Nanofluidics, Inc., the company adopted its current name, Pacific Biosciences of California, Inc., in 2005. Its corporate headquarters are situated in Menlo Park, California.
PACB Financial Timeline
Browse a chronological timeline of Pacific Biosciences of California, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 9 Feb 2027
EPS estimate is -$0.13, while revenue estimate is $47.45m.
Upcoming earnings on 3 Nov 2026
EPS estimate is -$0.13, while revenue estimate is $43.82m.
Upcoming earnings on 3 Aug 2026
EPS estimate is -$0.13, while revenue estimate is $42.90m.
Earnings released on 7 May 2026
EPS came in at -$0.03 surpassing the estimated -$0.17 by +82.35%, while revenue for the quarter reached $37.18m , missing expectations by -6.92%.
Earnings released on 12 Feb 2026
EPS came in at -$0.12 surpassing the estimated -$0.19 by +36.84%, while revenue for the quarter reached $44.65m , beating expectations by +3.74%.
Earnings released on 5 Nov 2025
EPS came in at -$0.12 surpassing the estimated -$0.16 by +25.00%, while revenue for the quarter reached $38.44m , missing expectations by -13.81%.
Earnings released on 7 Aug 2025
EPS came in at -$0.13 surpassing the estimated -$0.18 by +27.78%, while revenue for the quarter reached $39.77m , missing expectations by -0.46%.
Earnings released on 8 May 2025
EPS came in at -$0.15 surpassing the estimated -$0.19 by +21.05%, while revenue for the quarter reached $37.15m , beating expectations by +0.69%.
Earnings released on 13 Feb 2025
EPS came in at -$0.20 matching the estimated -$0.20, while revenue for the quarter reached $39.22m , missing expectations by -3.58%.
Earnings released on 7 Nov 2024
EPS came in at -$0.22 matching the estimated -$0.22, while revenue for the quarter reached $39.97m , missing expectations by -4.73%.
Earnings released on 7 Aug 2024
EPS came in at -$0.20 surpassing the estimated -$0.24 by +16.67%, while revenue for the quarter reached $36.01m , missing expectations by -11.91%.
Earnings released on 9 May 2024
EPS came in at -$0.29 falling short of the estimated -$0.28 by -3.57%, while revenue for the quarter reached $38.81m , missing expectations by -10.66%.
Earnings released on 15 Feb 2024
EPS came in at -$0.31 falling short of the estimated -$0.29 by -6.90%, while revenue for the quarter reached $58.36m , beating expectations by +1.51%.
Earnings released on 30 Oct 2023
EPS came in at -$0.26 surpassing the estimated -$0.33 by +21.21%, while revenue for the quarter reached $55.69m , beating expectations by +14.21%.
Earnings released on 2 Aug 2023
EPS came in at -$0.28 surpassing the estimated -$0.32 by +12.50%, while revenue for the quarter reached $47.57m , beating expectations by +18.05%.
Earnings released on 2 May 2023
EPS came in at -$0.36 falling short of the estimated -$0.33 by -9.09%, while revenue for the quarter reached $38.90m , beating expectations by +13.15%.
Earnings released on 16 Feb 2023
EPS came in at -$0.37 falling short of the estimated -$0.36 by -2.78%, while revenue for the quarter reached $27.35m , beating expectations by +4.39%.
Earnings released on 7 Nov 2022
EPS came in at -$0.34 falling short of the estimated -$0.33 by -3.03%, while revenue for the quarter reached $32.31m , missing expectations by -8.73%.
Earnings released on 3 Aug 2022
EPS came in at -$0.32 matching the estimated -$0.32, while revenue for the quarter reached $35.47m , beating expectations by +0.87%.
Earnings released on 4 May 2022
EPS came in at -$0.37 falling short of the estimated -$0.31 by -19.35%, while revenue for the quarter reached $33.17m , beating expectations by +0.79%.
Earnings released on 15 Feb 2022
EPS came in at -$0.31 falling short of the estimated -$0.28 by -10.71%, while revenue for the quarter reached $36.02m , missing expectations by -0.28%.
Earnings released on 2 Nov 2021
EPS came in at -$0.23 falling short of the estimated -$0.21 by -9.52%, while revenue for the quarter reached $34.89m , beating expectations by +5.08%.
Earnings released on 3 Aug 2021
EPS came in at -$0.21 matching the estimated -$0.21, while revenue for the quarter reached $30.61m , beating expectations by +2.07%.
PACB Stock Performance
Access detailed PACB performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
